持续输注利多卡因作为小儿手术后急性疼痛管理的镇痛辅助的初步经验

Deanna F. Couser, Catherine Roth, Miranda Holbrook, Sibelle Aurelie Yemele Kitio, Sharon Wrona, David Martin, Joseph D. Tobias
{"title":"持续输注利多卡因作为小儿手术后急性疼痛管理的镇痛辅助的初步经验","authors":"Deanna F. Couser, Catherine Roth, Miranda Holbrook, Sibelle Aurelie Yemele Kitio, Sharon Wrona, David Martin, Joseph D. Tobias","doi":"10.14740/ijcp522","DOIUrl":null,"url":null,"abstract":"Background: Lidocaine is a local anesthetic of the amide class that has been used for various therapeutic interventions. Its potential analgesic effects have been reported in anecdotal reports and larger clinical trials. Methods: We retrospectively reviewed our 24-month experience with the use of lidocaine outside of the intensive care unit (ICU) setting as an adjunct to acute pain management following major surgical procedures in children and adolescents. Results: The study cohort included 168 patients (mean age 13.8 years). The majority of patients (N = 142) underwent a posterior spinal fusion for treatment of scoliosis (idiopathic or neuromuscular). Thirty-one patients received a bolus dose followed by an infusion starting at 0.2 to 2 mg/kg/h (average dose 0.97 mg/kg/h). Most patients (86.3%) received a continuous lidocaine infusion for 1 - 3 days at an average dose of 1 mg/kg/h. Lidocaine was infused for a total of 503 days in the study cohort of 168 patients. Despite that these were major surgical procedures, pain scores were generally acceptable. The lidocaine infusion was discontinued or decreased in eight patients due to concerns of adverse effects. Adverse effects were noted in 38 days of the 503 days of infusion (7.6%). A total of 29 patients (17.3%) experienced at least one adverse effect. The majority of these were related to the central nervous system (CNS) including blurred vision, dizziness, drowsiness/difficult to arouse, delirium, hallucinations, agitation, confusion, delirium, hallucinations, agitation, and confusion. Conclusions: We present the largest study to date outlining the use of lidocaine as an adjunct to acute pain management in children and adolescents. These preliminary data suggest that with enhanced clinical observation for signs of potential toxicity and increased clinical monitoring of vital signs, the lidocaine infusion can be administered on the inpatient ward without routine serum concentration monitoring. The current cohort and other studies in pediatric patients provide a background for prospective studies to evaluate dosing regimens, optimal patient populations, and analgesic efficacy. Int J Clin Pediatr. 2023;12(2):29-36 doi: https://doi.org/10.14740/ijcp522","PeriodicalId":13773,"journal":{"name":"International Journal of Clinical Pediatrics","volume":"169 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preliminary Experience With a Continuous Lidocaine Infusion as an Analgesia Adjunct for Acute Pain Management Following Surgery in Pediatric Patients\",\"authors\":\"Deanna F. Couser, Catherine Roth, Miranda Holbrook, Sibelle Aurelie Yemele Kitio, Sharon Wrona, David Martin, Joseph D. Tobias\",\"doi\":\"10.14740/ijcp522\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Lidocaine is a local anesthetic of the amide class that has been used for various therapeutic interventions. Its potential analgesic effects have been reported in anecdotal reports and larger clinical trials. Methods: We retrospectively reviewed our 24-month experience with the use of lidocaine outside of the intensive care unit (ICU) setting as an adjunct to acute pain management following major surgical procedures in children and adolescents. Results: The study cohort included 168 patients (mean age 13.8 years). The majority of patients (N = 142) underwent a posterior spinal fusion for treatment of scoliosis (idiopathic or neuromuscular). Thirty-one patients received a bolus dose followed by an infusion starting at 0.2 to 2 mg/kg/h (average dose 0.97 mg/kg/h). Most patients (86.3%) received a continuous lidocaine infusion for 1 - 3 days at an average dose of 1 mg/kg/h. Lidocaine was infused for a total of 503 days in the study cohort of 168 patients. Despite that these were major surgical procedures, pain scores were generally acceptable. The lidocaine infusion was discontinued or decreased in eight patients due to concerns of adverse effects. Adverse effects were noted in 38 days of the 503 days of infusion (7.6%). A total of 29 patients (17.3%) experienced at least one adverse effect. The majority of these were related to the central nervous system (CNS) including blurred vision, dizziness, drowsiness/difficult to arouse, delirium, hallucinations, agitation, confusion, delirium, hallucinations, agitation, and confusion. Conclusions: We present the largest study to date outlining the use of lidocaine as an adjunct to acute pain management in children and adolescents. These preliminary data suggest that with enhanced clinical observation for signs of potential toxicity and increased clinical monitoring of vital signs, the lidocaine infusion can be administered on the inpatient ward without routine serum concentration monitoring. The current cohort and other studies in pediatric patients provide a background for prospective studies to evaluate dosing regimens, optimal patient populations, and analgesic efficacy. Int J Clin Pediatr. 2023;12(2):29-36 doi: https://doi.org/10.14740/ijcp522\",\"PeriodicalId\":13773,\"journal\":{\"name\":\"International Journal of Clinical Pediatrics\",\"volume\":\"169 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Pediatrics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14740/ijcp522\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/ijcp522","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:利多卡因是一种酰胺类局部麻醉剂,已被用于多种治疗干预。其潜在的镇痛作用已在轶事报告和较大的临床试验中报道。方法:我们回顾性回顾了24个月来在重症监护病房(ICU)外使用利多卡因作为儿童和青少年重大外科手术后急性疼痛治疗的辅助治疗的经验。结果:研究队列包括168例患者(平均年龄13.8岁)。大多数患者(N = 142)接受后路脊柱融合术治疗脊柱侧凸(特发性或神经肌肉型)。31例患者先给药,然后以0.2 ~ 2mg /kg/h的剂量开始输液(平均剂量0.97 mg/kg/h)。大多数患者(86.3%)连续输注利多卡因1 - 3天,平均剂量为1mg /kg/h。在168名患者的研究队列中,利多卡因输注共503天。尽管这些都是主要的外科手术,但疼痛评分通常是可以接受的。由于担心不良反应,8例患者停止或减少利多卡因输注。503天输注中有38天出现不良反应(7.6%)。共有29例患者(17.3%)经历了至少一次不良反应。其中大多数与中枢神经系统(CNS)有关,包括视力模糊、头晕、嗜睡/难以唤醒、谵妄、幻觉、躁动、混乱、谵妄、幻觉、躁动和混乱。结论:我们提出了迄今为止最大的研究,概述了利多卡因作为儿童和青少年急性疼痛管理的辅助治疗。这些初步数据表明,加强临床对潜在毒性体征的观察和临床对生命体征的监测,利多卡因输注可以在不进行常规血清浓度监测的情况下在住院病房进行。目前在儿科患者中的队列研究和其他研究为评估给药方案、最佳患者群体和镇痛效果的前瞻性研究提供了背景。国际儿科临床杂志。2023;12(2):29-36 doi: https://doi.org/10.14740/ijcp522
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Preliminary Experience With a Continuous Lidocaine Infusion as an Analgesia Adjunct for Acute Pain Management Following Surgery in Pediatric Patients
Background: Lidocaine is a local anesthetic of the amide class that has been used for various therapeutic interventions. Its potential analgesic effects have been reported in anecdotal reports and larger clinical trials. Methods: We retrospectively reviewed our 24-month experience with the use of lidocaine outside of the intensive care unit (ICU) setting as an adjunct to acute pain management following major surgical procedures in children and adolescents. Results: The study cohort included 168 patients (mean age 13.8 years). The majority of patients (N = 142) underwent a posterior spinal fusion for treatment of scoliosis (idiopathic or neuromuscular). Thirty-one patients received a bolus dose followed by an infusion starting at 0.2 to 2 mg/kg/h (average dose 0.97 mg/kg/h). Most patients (86.3%) received a continuous lidocaine infusion for 1 - 3 days at an average dose of 1 mg/kg/h. Lidocaine was infused for a total of 503 days in the study cohort of 168 patients. Despite that these were major surgical procedures, pain scores were generally acceptable. The lidocaine infusion was discontinued or decreased in eight patients due to concerns of adverse effects. Adverse effects were noted in 38 days of the 503 days of infusion (7.6%). A total of 29 patients (17.3%) experienced at least one adverse effect. The majority of these were related to the central nervous system (CNS) including blurred vision, dizziness, drowsiness/difficult to arouse, delirium, hallucinations, agitation, confusion, delirium, hallucinations, agitation, and confusion. Conclusions: We present the largest study to date outlining the use of lidocaine as an adjunct to acute pain management in children and adolescents. These preliminary data suggest that with enhanced clinical observation for signs of potential toxicity and increased clinical monitoring of vital signs, the lidocaine infusion can be administered on the inpatient ward without routine serum concentration monitoring. The current cohort and other studies in pediatric patients provide a background for prospective studies to evaluate dosing regimens, optimal patient populations, and analgesic efficacy. Int J Clin Pediatr. 2023;12(2):29-36 doi: https://doi.org/10.14740/ijcp522
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信